News

2017

ReachBio Research Labs Offers New NK (V158+) Cells Optimized for ADCC Assays online

May 9, 2017

ReachBio Research Labs is now offering sourced, enriched and tested primary natural killer (V158+) cells from normal and healthy donors to facilitate better antibody research through ADCC assays….. >read more 

ReachBio’s COO, Rob Chaney, talks cellPrism® and growth with CEOCFO Magazine

April 24, 2017

Blood and Bone Marrow Primary Cell Contract Research Services using the CellPrism® Platform to provide Predictive and Investigative Toxicology, Immuno-Oncology, …. >read more 

Applied Pharmaceutical Toxicology (APT) 2017

April 17, 2017

ReachBio Research Labs in San Francisco for the 2017 Applied Pharmaceutical Toxicology Conference May 15-17…. >read more 

SOT 56th Annual Meeting and ToxExpo

February 15, 2017

ReachBio Research Labs will be exhibiting at the Society of Toxicology 56th Annual Meeting and ToxExpo…. >read more 

ReachBio Research Labs Launches a New Drug Development Platform, cellPrism®

January 31, 2017 

ReachBio Research Labs Launches a New Drug Development Platform, cellPrism®…. >read more 

2016

Human PBMCs Available Online

June 20, 2016 

ReachBio Research Labs now makes it easy for you to purchase Human Peripheral Blood Mononuclear Cells (PBMCs)…. >read more 

World Preclinical Congress 2016

June 01, 2016 

Join us June 15-17, 2016 at the 15th Annual World Preclinical Congress in Boston, MA…. >read more 

AAI Annual Meeting & Immunology 2016

April 20, 2016 

We’re excited to be in our own backyard for this year’s Immunology 2016! ReachBio Research Labs will be exhibiting at Immunology 2016 in Seattle, WA…. >read more 

Society of Toxicology 55th Annual Meeting and ToxExpo

March 04, 2016 

The Society of Toxicology 55th Annual Meeting and ToxExpo is next week! We’ll be exhibiting at ToxExpo…. >read more 

2015

Happy New Year from ReachBio Research Labs!

Dec 31, 2015 

It’s been a good year for growth at ReachBio Research Labs! We’ve really enjoyed working…. >read more 

Thank you for visiting us at ACT 2015!

June 01, 2015 

Thank you to everyone who took the time to visit with us at the American College of Toxicology (ACT) 2015 36th Annual Meeting,…. >read more 

2014

Effects of Compounds on Thrombopoiesis: Beyond the CFU-Mk Colony Assay

September 11, 2014

The CFU-Mk assay is a robust and predictive in vitro assay for evaluating the toxicity of test compounds on megakaryocytic progenitors…. >read more 

Hemotoxicity Testing: Predictive Lineage-Specific In Vitro Assay Services by ReachBio Research Labs

May 12, 2014 

If your drug development program has a particular lineage-specific hemotoxicity issue such as neutropenia (myeloid lineage toxicity)…. >read more 

Seattle-Based Contract Research Organization ReachBio Unveils New Website, Rebrands as ReachBio Research Labs

April 28, 2014 

ReachBio LLC announced today that it is extending its trade name and will start doing business as ReachBio Research Labs…. >read more 

ReachBio’s Posters Presented at SOT 2014 Are Now Available to Download

April 10, 2014 

ReachBio Research Labs presented two posters at the recent Society of Toxicology conference in Phoenix, AZ. One on comparing…. >read more 

SOT 2014 Posters Available for Download!

February 27, 2014 

ReachBio Research Labs presented the following posters at the recent Society of Toxicology conference in Phoenix, AZ…. >read more 

Hemotoxicity Testing Services – Are you Eligible for Multi-Assay Discounts?

February 15, 2014 

Our in vitro hemotoxicity testing services can provide valuable predictive information regarding compound-induced hemotoxicity on specific lineages…. >read more 

2013

PeloBiotech to Distribute ReachBio’s Products in Germany, Austria and Switzerland

October 28, 2013

ReachBio LLC (Seattle, WA, USA) announced today that it has signed an agreement with PeloBiotech GmbH (Munich, Germany) giving PeloBiotech exclusive distribution rights to ReachBio’s full product line …. >read more 

2010

ReachBio Tutorial About Predictive Hemotoxicity Testing Published in Genetic Engineering and Biotechnology News

February 15, 2010

Seattle-based contract research organization ReachBio LLC announced today that Genetic Engineering and Biotechnology News (GEN) has published a Tutorial entitled “Predicting Drug-Induced Myelotoxicity”…. >read more 

2008

ReachBio Launches HemoRANK-TKI Service Package for Predicting Myelotoxicity of New Tyrosine Kinase Inhibitors

September 15, 2008

ReachBio LLC announced today the launch of HemoRANKTM-TKI, an in vitro assay service package that helps predict the potential of novel therapeutic tyrosine kinase inhibitors (TKIs) to cause clinical hemotoxicity (myelotoxicity or neutropenia) …. >read more 

ReachBio Partners with Axiogenesis to Distribute Novel Cell-Based Products in North America

Februrary 27, 2008

ReachBio LLC (Seattle, WA) announced today that it will distribute the full product line of Axiogenesis AG (Cologne, Germany) to the North American life science research and drug discovery market…. >read more 

2007

Experienced Stem Cell Industry Management Team Opens Doors to New Contract Services Business with launch of ReachBio LLC

September 19, 2007

ReachBio LLC announced today the official opening of its business operations. Located in Seattle WA…. >read more